Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in a $2.9 billion cash transaction, paying $53.00 per share. The offer represents a 34% premium to Soleno’s closing price on April 2, 2026, and a 51% premium to its 30‑day volume‑weighted average price. The parties expect the deal to close within 90 days, subject to customary regulatory and shareholder approvals.
The acquisition brings Soleno’s flagship product, VYKAT XR, into Neurocrine’s portfolio. VYKAT XR received FDA approval in March 2025 and launched in the United States in the second quarter of 2025. In 2025 the drug generated $190 million in revenue, with $92 million coming in the fourth quarter—a 40% increase over the third quarter. Soleno reported a net income of $20.9 million for 2025, marking the first profitable year for the company.
Strategically, the deal expands Neurocrine’s rare‑disease focus into a high‑margin orphan‑drug market. The addition complements Neurocrine’s existing products, INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont), and strengthens its position in endocrinology and metabolic disease. The transaction is expected to accelerate revenue growth and diversify the company’s therapeutic pipeline.
Financially, the purchase will be funded with cash on hand and a modest amount of pre‑payable debt. If the agreement is terminated, Soleno would pay a $95.25 million fee; if antitrust approvals fail, Neurocrine would pay a $141.5 million fee. These terms provide clear exit costs for both parties.
Investors have noted the premium paid for Soleno and the cash outlay required by Neurocrine. The premium reflects the market’s confidence in VYKAT XR’s commercial potential, while the cash commitment highlights concerns about execution risk and the impact on Neurocrine’s balance sheet.
Management comments underscore the strategic fit. CEO Kyle Gano said the transaction “advances Neurocrine’s mission to deliver life‑changing treatments while accelerating our revenue growth and portfolio diversification.” Vice president Samir Siddhanti highlighted VYKAT XR’s strong 2025 performance, and Soleno chairman Anish Bhatnagar praised Neurocrine’s experience in rare‑disease commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.